UPDATE: COVID-19 Read the Message

Press Releases

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. PTC Therapeutics disavows any obligation to update the information contained in such press releases after the date of their issuance.

Date Title and Summary View
Nov 18, 2020
SOUTH PLAINFIELD, N.J. , Nov. 18, 2020 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT), today announced that the United States (U.S.) Food and Drug Administration (FDA) has granted PTC596 both Orphan Drug Designation and Fast Track designation for the potential treatment of leiomyosarcoma
Additional Formats
Nov 17, 2020
- Initial clinical trial results expected in 1H 2021 - SOUTH PLAINFIELD, N.J. , Nov. 17, 2020 /PRNewswire/ --   PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the initiation of a Phase 1 clinical trial to evaluate PTC518 in healthy volunteers. PTC518 was identified from PTC's splicing
Additional Formats
Nov 16, 2020
- AADC deficiency associated with high and accumulating disease burden, demonstrating the need for access to an effective therapy -   - Patient and caregiver quality of life study reveals real-life impact of nonsense mutation Duchenne muscular dystrophy and reinforces value of treatment - SOUTH
Additional Formats
Oct 29, 2020
- Evrysdi™ makes rapid progress with multiple international approvals and strong U.S. launch -   - Total net revenue of $118.4 million, 66% YoY increase; Total net product revenue of $82.7 million, 16% YoY increase -   - Initiated registration-directed trial with vatiquinone (PTC743) for
Additional Formats
Oct 28, 2020
SOUTH PLAINFIELD, N.J. , Oct. 28, 2020 /PRNewswire/ --  PTC Therapeutics, Inc.  (NASDAQ: PTCT) today announced that on October 23, 2020 it approved non-statutory stock options to purchase an aggregate of 18,610 shares of its common stock and 6,860 restricted stock units ("RSUs"), each representing
Additional Formats
Oct 28, 2020
SOUTH PLAINFIELD, N.J. , Oct. 28, 2020 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company overview at the following conferences: Credit Suisse 29 th Annual Virtual Healthcare Conference Wednesday, November 11 th at 9:30 a.m.
Additional Formats
Oct 26, 2020
- Global Phase 2/3 trial now enrolling patients with highly morbid unmet medical condition - SOUTH PLAINFIELD, N.J. , Oct. 26, 2020 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT), today announced the initiation of a registration-directed Phase 2/3 clinical trial to evaluate vatiquinone
Additional Formats
Oct 22, 2020
- Massachusetts signs proclamation declaring Oct.23 as AADC Deficiency Awareness Day -   - PTC hosts Facebook Live event featuring leaders from AADC Family Network, MassBio, and Boston Children's Hospital - SOUTH PLAINFIELD, N.J. , Oct. 22, 2020 /PRNewswire/ --  PTC Therapeutics, Inc.
Additional Formats
Oct 21, 2020
- Broad approval in Brazil based on data from multiple pivotal trials -   - NDA filed with Japan's MHLW under Priority Review; Milestone triggers $7.5M payment from Roche - SOUTH PLAINFIELD, N.J. , Oct. 21, 2020 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Evrysdi™
Additional Formats
Oct 15, 2020
SOUTH PLAINFIELD, N.J. , Oct. 15, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its third quarter 2020 financial results and provide an update on the company's business and outlook on Thursday, October 29,
Additional Formats